Abstract OT2-06-01: Highly innovative personalized RNA-immunotherapy for patients with triple negative breast cancerM Schmidt, Uğur Şahin, Andreas N. Kuhn et al.|Cancer Research|2019Cited by 10
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Katrin Frenzel et al.|Annals of Oncology|2018Cited by 4
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Katrin Frenzel et al.|Cancer Research|2019Cited by 3
Abstract CT221: Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)Ludwig Heesen, Uğur Şahin, Katrin Frenzel et al.|Clinical Trials|2019Cited by 2
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancerKatrin Frenzel, Uğur Şahin, Ludwig Heesen et al.|Annals of Oncology|2017Cited by 2